The combination of a low PEG (0.3x) and discounted EV/EBITDA (5.4x) is the most compelling valuation signal, indicating that if Lionsgate can sustain its forecasted earnings CAGR, the stock offers a sizable upside relative to peers.
The forward P/E’s placement in the top 5% of historical observations means any miss on earnings guidance could trigger a sharp revaluation; a 10% earnings shortfall would instantly push the forward P/E above 60x, amplifying downside risk.
| Metric | Historical DCF | Analyst DCF |
|---|---|---|
| Growth Assumption | 3.5% (normalized) (10Y CAGR) | Analyst Rev × 9.2% margin |
| PV of FCF | $1.18B | $1.44B |
| Terminal Value (PV) | $18.49B | $22.53B |
| Enterprise Value | $19.67B | $23.96B |
| Equity Value | $15.88B | $20.17B |
| Implied Stock Price | $221.11 | $280.88 |
| Upside/Downside | +1537.9% | +1980.6% |
| WACC \ Growth | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 2.8% | $1172 | ||||
| 3.8% | $229 | $397 | $1125 | ||
| 4.8% | $107 | $147 | $219 | $381 | $1081 |
| 5.8% | $58 | $76 | $101 | $140 | $209 |
| 6.8% | $32 | $42 | $54 | $71 | $95 |
| WACC \ Growth | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 2.8% | $1439 | ||||
| 3.8% | $291 | $496 | $1382 | ||
| 4.8% | $141 | $191 | $278 | $475 | $1329 |
| 5.8% | $82 | $104 | $134 | $182 | $266 |
| 6.8% | $51 | $62 | $78 | $98 | $128 |
| Method | Implied Value | Upside/Downside | Basis |
|---|---|---|---|
| P/E (Peer) | $11.60 | -14.1% | Peer median P/E (44.6x) × Forward EPS ($0.26) |
| EV/EBITDA (Peer) | $48.99 | +262.9% | Peer median EV/EBITDA (15.1x) × EBITDA - Net Debt |
| P/S (Peer) | $34.86 | +158.2% | Peer median P/S (2.60x) × Revenue per Share |
| DCF | $221.11 | +1537.9% | Revenue × FCF Margin projection (normalized FCF) |
| Analyst Target | $14.50 | +7.4% | Consensus of 3 analysts |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net